Case Reports
28 December 2021
Vol. 14 No. 2 (2022)
Improvement of atopic dermatitis and alopecia universalis with dupilumab
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
1198
Views
481
Downloads
37
HTML
Authors
Dupilumab is an interleukin-4 receptor alpha antagonist that showed significant improvement of atopic dermatitis (AD). Many reports have shown significant resolution of alopecia areata, alopecia universalis and alopecia totalis after dupilumab treatment for AD. We present one of reported cases that showed improvement of underlying alopecia universalis treated with dupilumab.
Altmetrics
Downloads
Download data is not yet available.
Citations
Howell MD, Kim BE, Gao P, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol 2009;124:R7-12.
Wollenberg A, Wetzel S, Burgdorf WHC, Haas J. Viral infections in atopic dermatitis: Pathogenic aspects and clinical management. J Allergy Clin Immunol 2003;112:667-74.
Kaminishi K, Soma Y, Kawa Y, Mizoguchi M. Flow cytometric analysis of IL-4, IL-13 and IFN-gamma expression in peripheral blood mononuclear cells and detection of circulating IL-13 in patients with atopic dermatitis provide evidence for the involvement of type 2 cytokines in the disease. J Dermatol Sci 2002;29:19-25.
Seegräber M, Srour J, Walter A, et al. Dupilumab for treatment of atopic dermatitis. Expert Rev Clin Pharmacol 2018;11:467-74.
Suárez-Fariñas M, Ungar B, Noda S, et al. Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17/TH22 skewing. J Allergy Clin Immunol 2015;136:1277-87.
Betz RC, Petukhova L, Ripke S, et al. Genome-wide meta-analysis in alopecia areata resolves HLA associations and reveals two new susceptibility loci. Nature Commun 2015;6:5966.
Call JE, Sahni S, Zug KA. Effectiveness of dupilumab in the treatment of both atopic dermatitis and alopecia universalis. Clini Case Rep 2020;8:1337-9.
Seegräber M, Srour J, Walter A, et al. Dupilumab for treatment of atopic dermatitis. Expert Rev Clin Pharmacol 2018;11:467-74.
Ständer S, Trense Y, Thaçi D, Ludwig RJ. Alopecia areata development in atopic dermatitis patients treated with dupilumab. J Eur Acad Dermatol Venereol 2020;34:e612-3.
Gruenstein D, Malik K, Levitt J. Full scalp hair regrowth in a 4-year-old girl with alopecia areata and atopic dermatitis treated with dupilumab. JAAD Case Rep 2020;6:1286-7.
How to Cite
Improvement of atopic dermatitis and alopecia universalis with dupilumab. (2021). Dermatology Reports, 14(2). https://doi.org/10.4081/dr.2022.9359
